APS Funds records ‘positive’ performance last year

The investment wing of APS Bank’s Fund range recorded a “positive” performance across all Fund products last year, the bank announced Monday.

In a statement, APS said results for its subsidiary ReAPS Asset Management Limited – which is owned in its entirety by the bank and is investment manager for the APS Fund range – were “encouraging”.

The APS Ethical Adventurous Fund delivered a return of 16.31%, which the bank said reflected its “higher allocation to global equities and growth-oriented assets, supported by selective exposure to companies aligned with sustainable business practices and strong governance standards”.

Its Ethical Balanced Fund achieved a return of 7.62%, “benefiting from diversified exposure across equities and fixed income instruments”. The APS Ethical Cautious Fund recorded a 4.88% gain, “consistent with its focus on capital preservation and lower volatility”.

Meanwhile, the APS Diversified Bond Fund posted a return of 0.77%, which the bank said reflected its “prudent interest rate and credit risk management”.

The APS Income Fund, structured as a prescribed fund, delivered a return of 1.46%, supported by income from Maltese bonds and dividend-paying local equities.

The bank said in its statement that the results “demonstrated the benefits of disciplined asset allocation and active management in a varied market environment”.

ReAPS Asset Management Limited managing director and APS Banks head of investment management Josef Portelli said the results “reflect our continued commitment to responsible investing, diversification and robust risk management”.

“Across ethical, bond and income strategies, the Funds delivered their objectives while navigating differing market conditions”, he said.

The statement noted that the quoted performance figures relate to Accumulator Share classes and refer to period between 1 January and 31 December 2025.

Total
0
Shares
Previous Article

Eden Leisure Group and InterContinental Malta donate €6,500 to Dar tal-Providenza

Next Article
Vivian Novartis

Vivian announces partnership with Novartis Pharma Services AG in Malta

Related Posts